Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $11.00.

Several equities research analysts recently weighed in on EVAX shares. Maxim Group started coverage on Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 target price for the company. Wall Street Zen lowered Evaxion A/S from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. JonesTrading started coverage on Evaxion A/S in a report on Tuesday, March 10th. They issued a “buy” rating and a $10.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a report on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th.

Institutional Investors Weigh In On Evaxion A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. acquired a new stake in Evaxion A/S in the 4th quarter worth approximately $38,000. Wesbanco Bank Inc. acquired a new position in shares of Evaxion A/S during the fourth quarter worth approximately $48,000. Finally, SmartHarvest Portfolios LLC acquired a new position in shares of Evaxion A/S during the fourth quarter worth approximately $72,000. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion A/S Trading Down 1.6%

Shares of NASDAQ EVAX opened at $3.72 on Tuesday. The stock has a market cap of $31.02 million, a price-to-earnings ratio of -2.82 and a beta of 0.19. The business has a 50 day simple moving average of $3.50 and a 200 day simple moving average of $4.75. Evaxion A/S has a 52 week low of $1.20 and a 52 week high of $12.15. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.85 and a current ratio of 5.85.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.